Reduced dose capecitabine is an effective and well-tolerated treatment in patients with metastatic breast cancer
| Autor: | L. El-Helw, Robert E. Coleman |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
Oncology
Adult medicine.medical_specialty Antimetabolites Antineoplastic Nausea medicine.medical_treatment Breast Neoplasms Gastroenterology Deoxycytidine Capecitabine Internal medicine medicine Humans Neoplasm Metastasis Adverse effect Survival analysis Aged Neoplasm Staging Chemotherapy Dose-Response Relationship Drug business.industry Cancer General Medicine Middle Aged medicine.disease Metastatic breast cancer Survival Analysis Treatment Outcome Toxicity Surgery Female Fluorouracil medicine.symptom business medicine.drug |
| Zdroj: | Breast (Edinburgh, Scotland). 14(5) |
| ISSN: | 0960-9776 |
| Popis: | Fifty-seven patients with metastatic breast cancer have been treated with reduced dose capecitabine 1g/m2 twice daily for 14 days repeated every 3 weeks after failure of a number of chemotherapy regimens or hormonal treatment. The overall objective response rate was 28% with 2% complete response rate and 26% partial response. Twenty nine percent objective response rate was achieved in 17 patients pretreated with anthracyclines and taxanes. The median duration of response and survival were 8.5 and 9 months, respectively. One and two year overall survival probabilities were 37% and 20%, respectively. The most common treatment-related adverse events (all grades) were hand-foot syndrome (HFS) (32%), nausea (21%) and diarrhoea (19%). Dose limiting toxicities, especially HFS were rare. Within the limits of phase II trial, this reduced dose of capecitabine appears as effective for advanced breast cancer as full dose capecitabine with a lower incidence of toxicity. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect